sirukumab   

GtoPdb Ligand ID: 7989

Synonyms: CNTO 136 | CNTO-136 | Plivensia (proposed trade name)
Compound class: Antibody
Comment: Sirukumab is a monoclonal antibody directed against interleukin 6 (IL-6), in development as an immunomodulator for the treatment of rheumatoid arthritis (RA). It is also being tested as an immunopsychiatry therapy to treat depression.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence BLAST search using the heavy chain variable region of sirukumab provides100% match to a sequence claimed in patent US7560112 [1], and to the antibody with designation AME-19a.
Immunopharmacology Comments
Sirukumab is an investigational immunomodulator, with the most advanced trials being in patients with rheumatoid arthritis.
Evidence supporting the potential anti-depressive action of IL-6 neutralising antibody therapy is reported in [7].
Immunopharmacology Disease
Disease X-Refs Comment References
Polymyalgia rheumatica Disease Ontology: DOID:853
Phase 3 clinical candidate for PMR (see NCT02899026).
Temporal arteritis Disease Ontology: DOID:13375
OMIM: 187360
Orphanet: ORPHA397
Phase 3 clinical candidate for temporal arteritis (giant cell arteritis)- see NCT02531633
Major depressive disorder; MDD Disease Ontology: DOID:1470
OMIM: 608516
Phase 2 clinical candidate for MDD (see NCT02473289).
Rheumatoid arthritis Disease Ontology: DOID:7148
OMIM: 180300
Phase 3 clinical candidate for RA (see NCT01856309).